PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histological confirmation of 1 of the following:
• * Ovarian epithelial carcinoma
• * Fallopian tube cancer
• * Primary peritoneal cancer
• * Advanced colorectal carcinoma
• * Other malignancy confined to the peritoneal cavity or peritoneal surfaces
• No lesion greater than 2 cm in greatest diameter based on surgical re-assessment
• Low burden of tumor in the abdominal or pelvic cavities and no clinically significant ascites
• Received potentially effective therapy when available (e.g., platinum/taxane for ovarian cancer, fluoropyrimidine-based therapy for colorectal cancer)
• No concurrent hematological malignancy (e.g., chronic lymphocytic leukemia or non-Hodgkin's lymphoma)
• No bilateral adrenal metastases
• No adrenal metastases in the remaining adrenal gland after adrenalectomy (including radical nephrectomy)
• No lung tumors 5 cm or more
• No pleural effusions (at least 25% of hemithorax) by radiography
• No CNS metastases by CT scan or MRI
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• Karnofsky 70-100%
• Life expectancy
• More than 3 months
• Hematopoietic
• WBC at least 3,000/mm\^3
• Absolute neutrophil count at least 1,000/mm\^3
• Platelet count at least 100,000/mm\^3
• Hemoglobin greater than 9 g/dL
• Hepatic
• Bilirubin no greater than 1.5 times upper limit of normal (ULN)
• AST and ALT no greater than 1.5 times ULN
• Alkaline phosphatase no greater than 1.5 times ULN
• No uncontrolled hepatic dysfunction
• No active hepatitis B or C
• Renal
• See Disease Characteristics
• Creatinine no greater than 1.6 mg/dL AND/OR
• Creatinine clearance at least 50 mL/min
• No uncontrolled renal dysfunction
• Cardiovascular
• No uncontrolled cardiovascular dysfunction
• No myocardial infarction within the past 6 months
• No life-threatening arrhythmias within the past 6 months
• Pulmonary
• See Disease Characteristics
• No uncontrolled pulmonary dysfunction
• No pulmonary atelectasis (lobar)
• No pulmonary infiltrates (lobar)
• No pulmonary consolidation (lobar or segmental)
• No baseline grade II dyspnea
• Adrenal
• See Disease Characteristics
• No uncontrolled adrenal dysfunction
• No known adrenal insufficiency
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No uncontrolled gastrointestinal dysfunction
• No neurological dysfunction
• No serious medical or psychological condition that would preclude study participation or increase the risk of adverse effects of the study treatment
• No history of serious immunodeficiency
• No active uncontrolled bacterial infection (including asymptomatic urinary tract infection)
• No contraindication to intraperitoneal therapy including the following:
• * Intra-abdominal infection
• * Dense widespread adhesions
• * Peritonitis
• * Periumbilical infection
• * Bowel obstruction
• * Ileostomy
• No hypersensitivity to eggs
• No continued contact with live birds (e.g., poultry farmers, veterinarians, laboratory technicians, pet store owners, breeders)
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• Not specified
• Chemotherapy
• See Disease Characteristics
• No more than 3 prior cytotoxic chemotherapy regimens
• More than 30 days since prior chemotherapy
• Endocrine therapy
• More than 14 days since prior systemic corticosteroids
• Radiotherapy
• More than 30 days since prior radiotherapy
• Surgery
• See Disease Characteristics
• No prior complete or partial lobectomy with removal of lung tissue at least segmental size
• No prior organ allograft
• Other
• Recovered from prior therapy
• More than 14 days since prior antiviral medication
• More than 4 weeks since prior immunosuppressive drugs
• No other concurrent investigational drugs
• No concurrent chronic immunosuppressive drugs (e.g., cyclosporine)
• No vaccination for influenza within 48 hours of study drug administration
• No concurrent hypoglycemic agents
• No concurrent antiretroviral therapy for HIV-positive patients
• No other concurrent anticancer therapy